Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio (BOLD) with an Early-Stage Biotech rating, saying the company’s combo approach for its lead asset BBI-355 comes with high risk.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLD:
- Boundless Bio Elects Directors and Ratifies Auditor
- Boundless Bio initiated with a Buy at H.C. Wainwright
- Boundless Bio Inc. Reports Q1 2025 Financial Results
- Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations
- Boundless Bio downgraded to Market Perform from Outperform at Leerink